| 1.44 0 (0%) | 07-26 10:45 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.69 | 1-year : | 1.97 |
| Resists | First : | 1.45 | Second : | 1.69 |
| Pivot price | 1.43 |
|||
| Supports | First : | 0.74 |
Second : | 0.31 |
| MAs | MA(5) : | 1.43 |
MA(20) : | 1.42 |
| MA(100) : | 0.64 |
MA(250) : | 1.39  |
|
| MACD | MACD : | 0.1 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 73.3 |
D(3) : | 68.8 |
| RSI | RSI(14): 83.4 | |||
| 52-week | High : | 3 | Low : | 0.2 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ AGRX ] has closed below upper band by 28.9%. Bollinger Bands are 92.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.45 - 1.46 | 1.46 - 1.47 |
| Low: | 1.41 - 1.42 | 1.42 - 1.43 |
| Close: | 1.43 - 1.44 | 1.44 - 1.45 |
Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was incorporated in 1997 and is headquartered in Princeton, New Jersey.
Thu, 25 Jul 2024
StockNews.com Begins Coverage on Agile Therapeutics (NASDAQ:AGRX) - Defense World
Wed, 17 Jul 2024
Agile Therapeutics (NASDAQ:AGRX) Share Price Passes Above 50 Day Moving Average of $0.68 - Defense World
Mon, 15 Jul 2024
Kuehn Law Encourages AGRX, SPR, ENV, and UMBF Investors to Contact Law Firm - Morningstar
Wed, 03 Jul 2024
STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Agile Therapeutics, Inc. - AGRX - PR Newswire
Wed, 26 Jun 2024
Agile Therapeutics to be acquired by Spain-based Insud for an enterprise value of ~$45M - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 7 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 9.2 (%) |
| Held by Institutions | 9.9 (%) |
| Shares Short | 222 (K) |
| Shares Short P.Month | 190 (K) |
| EPS | -0.52 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -1.51 |
| Profit Margin | -36.3 % |
| Operating Margin | -48.3 % |
| Return on Assets (ttm) | -75.8 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 49.9 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 3.13 |
| EBITDA (p.s.) | -2.27 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -10 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | -2.77 |
| PEG Ratio | 0 |
| Price to Book value | -0.96 |
| Price to Sales | 0.45 |
| Price to Cash Flow | -0.95 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|